PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement PDS Biotech (NASDAQ: PDSB) reported full-year 2025 results and clinical updates on March 30, 2026. The company amended its VERSATILE-003 Phase 3 protocol to add PFS as an interim primary endpoint to enable a potential accelerated approval pathway while preserving overall survival for full approval.Early PDS01ADC Phase 2 data showed median PFS of 9.6 months and a 40% median PSA decline in mCRPC; new U.S. and Japan patents extend Versamune platform protection into the 2040s. Full-year net loss was $34.5M; cash was $26.7M as of Dec 31, 2025.

#PDSB PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

www.stocktitan.net/news/PDSB/pds-biotech-re...

PDS Biotech pairs 2025 results with a clinical update on March 30 A webcast and conference call starts at 8 a.m. ET on March 30. PDS Biotech will cover year-end 2025 results, clinical programs and corporate updates.

#PDSB PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

www.stocktitan.net/news/PDSB/pds-biotech-an...

Ontario school boards don't need "supervision" they need support.

#onted #pdsb #ycdsb

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 PDS Biotech (Nasdaq: PDSB) announced a U.S. Notice of Allowance for a patent covering PDS0101 (U.S. Application No. 16/210,750) titled “Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes.” The patent will grant composition and method-of-use claims and adds to an existing global IP estate. Combined with anticipated U.S. biologics exclusivity, the company expects approximately 20 years of market protection for PDS0101. PDS0101 is in the Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancer. The company submitted a protocol amendment to FDA proposing PFS as an earlier primary endpoint to support potential accelerated approval while median overall survival remains the primary endpoint for full approval.

#PDSB PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint PDS Biotech (NASDAQ: PDSB) submitted a protocol amendment to the FDA on Jan 9, 2026 to change the Phase 3 VERSATILE-003 trial's primary endpoint to progression-free survival (PFS), enabling earlier evaluation with significant statistical power and potentially supporting an accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer. Median overall survival (mOS) and safety remain required for full FDA approval. The amendment follows a constructive Type C meeting with the FDA in December 2025 and is supported by positive final VERSATILE-002 results reporting promising mOS and durable PFS.

#PDSB PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS

#PDSB PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) PDS Biotech (Nasdaq: PDSB) announced the FDA accepted its request for a Type C meeting, scheduled for December 2025, to discuss a proposed amendment to the Phase 3 VERSATILE-003 trial.The amendment would make progression-free survival (PFS) a surrogate primary endpoint evaluable earlier with statistical power, potentially enabling an accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer. Median overall survival (mOS) will remain the primary endpoint for full approval. The company cites positive final VERSATILE-002 results showing promising mOS and durable PFS in patients with CPS ≥ 1. FDA meeting minutes are expected in January 2026.

#PDSB PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing VERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00

#PDSB PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

www.stocktitan.net/news/PDSB/pds-biotech-re...

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering PDS Biotechnology (Nasdaq: PDSB) announced a registered direct offering to sell 5,800,000 common shares (or pre-funded warrants) at $0.91 per share with accompanying warrants to purchase up to 5,800,000 shares at a $1.00 exercise price.Initial gross proceeds are expected to be approximately $5.3 million at closing on or about Nov 12, 2025, with up to an additional $5.8 million if all warrants are exercised for cash. The company reported approximately $26.2 million cash as of Sept 30, 2025 (preliminary unaudited).Proceeds are intended to support the VERSATILE-003 Phase 3 trial, planned FDA protocol discussions, R&D, and general corporate purposes. The company also agreed to amend existing warrants to reduce the exercise price from $1.50 to $1.00, exercisable six months after closing.

#PDSB PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

www.stocktitan.net/news/PDSB/pds-biotechnol...

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 PDS Biotechnology (Nasdaq: PDSB) presented translational and clinical data at SITC 2025 showing immune-driven activity for two investigational therapies: PDS0101 (HPV16-targeted immunotherapy) and PDS01ADC (tumor-targeting IL-12 immunocytokine).Key findings: a 50‑patient analysis of PDS0101 combinations showed broad immune activation and blood proteomic biomarkers that predicted clinical benefit; PDS01ADC monotherapy increased multifunctional NK cells and expanded stem-like memory CD8/CD4 T cells in 28 patients, with increases linked to clinical responses or disease stabilization.

#PDSB PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

www.stocktitan.net/news/PDSB/pds-biotechnol...

Trade Alerts, Thursday November 6, 2025 – Crystal Equity Research

Small-cap stocks in new ADX uptrend, Thu Nov 6th - #ATPC #UFPT #SRTS #RIGL #PDSB #FRBA #EOLS #BFST #ACNT #TDC #MITT #FSLY #DBI #BGS - More: crystalequityresearch.com/trade-alerts... - #smallcap

#PDSB PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer PDS Biotech (Nasdaq: PDSB) requested an FDA meeting on Oct 29, 2025 to pursue an expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer after final VERSATILE-002 results.Key data: median progression-free survival (mPFS) 6.3 months and median overall survival (mOS) 39.3 months. The company proposed amending the VERSATILE-003 Phase 3 protocol to add PFS as an earlier primary endpoint, reduce enrolled patient numbers while maintaining statistical power, and enable a potential accelerated approval if PFS is met. While the amendment is under FDA review, enrollment in VERSATILE-003 is temporarily paused but treatment for enrolled patients will continue.

#PDSB PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

www.stocktitan.net/news/PDSB/pds-biotech-to...

Trade Alerts, Monday September 8, 2025 – Crystal Equity Research

Small-cap stocks with bearish MACD Xs, Mon Sept 8th - #VIRC #OKUR #NBN #MOGO #JBSS #HIVE #GASS #FGEN #EQ #SNT #DYN #CCNE #ALXO #YEXT #WTI #SD #PDS #PACK #PDSB #NXDR #INVX #HE #GRNT #EGY #CYD #BFS #ALEX - More: crystalequityresearch.com/trade-alerts... - #smallcap

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer PDS Biotechnology (Nasdaq: PDSB) has announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 + Keytruda® in HPV16-positive first-line recurrent/metastatic head and neck cancer patients. The study demonstrated a remarkable median overall survival (mOS) of 39.3 months in patients with CPS ≥ 1, significantly outperforming the best published standard of care result of 17.9 months.The trial enrolled 53 patients and showed durable patient survival promoted by high levels of long-lasting HPV16-specific CD8+ T cells. The treatment combination was well-tolerated with no patients discontinuing due to treatment-related adverse events. The company plans to publish the full dataset later this year, while its VERSATILE-003 Phase 3 trial is currently in progress.

#PDSB PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDSB Loss Improves as Costs Drop | The Motley Fool

#PDSB #f29bb470-ad28-4b75-86d0-a11cae7fad51 #data-news

Origin | Interest | Match

PDS Biotech's Cancer Drug Hits Key Trial Goal as Q2 Losses Widen to $9.4M Cancer immunotherapy firm reports expanded colorectal cancer trial after strong response rates, while Q2 losses increase to $9.4M. ASCO data highlights HPV treatment progress. See results.

#PDSB PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

www.stocktitan.net/news/PDSB/pds-biotech-re...

Cancer Immunotherapy Developer PDS Biotech Announces Q2 Results and Clinical Program Updates Late-stage cancer immunotherapy company PDS Biotech schedules Q2 earnings call with clinical program updates for August 13. Join the discussion. Get insights.

#PDSB PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

www.stocktitan.net/news/PDSB/pds-biotech-an...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Thu Jul 17th - #NEXM #CEPO #PDSB #NB #KLRS #GAME #CDNA #BCLI #OPAD #EB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results Latest results reveal positive response rates in metastatic colorectal cancer treatment trial. NCI-led study advances to expanded enrollment phase. See full data.

#PDSB PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

www.stocktitan.net/news/PDSB/pds-biotech-an...

📸 Help us show the reality on the ground.
If you're teaching or working in a hot classroom, send us a photo of the temperature (thermostat, thermometer, etc.) to vickitab@etfopeel or felipep@etfopeel.com. Let’s make the impact visible. #ETFO #SafeSchools #PDSB

PDSB classrooms are sweltering—many with no A/C, just fans + makeshift “cooling centres.” With humidex near 46°C, this isn’t just hot—it’s unsafe. Students + staff deserve better. #OntEd #PDSB #HeatWave #UnsafeAtSchool
@BmptGuardian @PointerSauga @CTVNews @CBC @globalnews @CityNewsTO

Through a hands-on project with @PeelSchools, Provenance Farms & Swiirl, teens explored regenerative agriculture.

Watch & vote for your favourite story - 3 teams will win $100!

👉 peelschools.org/news/pdsb-stud…

#PDSB #Sustainability #StudentVoices #WereAllInThisTogether #VoteNow #PeelSchools

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update PDS Biotech (PDSB) reported its Q1 2025 financial results and provided clinical updates. The company has initiated the VERSATILE-003 Phase 3 trial for Versamune® HPV in HPV16-positive head and neck cancer, with Mayo Clinic sites recently added. The trial will include approximately 350 patients and received FDA Fast Track designation. Financial highlights include a net loss of $8.5 million ($0.21 per share), improved from $10.6 million in Q1 2024. R&D expenses decreased to $5.8 million from $6.7 million, while G&A expenses were $3.3 million. The company's cash balance stood at $40 million as of March 31, 2025. PDS Biotech also completed a registered direct offering raising approximately $11 million, with potential for additional $11 million from warrant exercises.

#PDSB PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

www.stocktitan.net/news/PDSB/pds-biotech-re...

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting PDS Biotechnology (NASDAQ: PDSB) presented preclinical data on their Infectimune®-based universal flu vaccine at IMMUNOLOGY2025™. Two key presentations highlighted promising results: Dr. Andrea Sant demonstrated that Infectimune® generated a significantly higher frequency of multifunctional influenza-specific CD4 T cells with cytotoxic properties, particularly targeting lung tissue in subjects with prior flu exposure. Dr. James Allen's research showed that Infectimune®-based vaccines using COBRA antigens effectively neutralized and protected against multiple H3N2 influenza strains from 2014-2021 in ferret studies. The research was funded and conducted by NIAID's CIVR-HRP, allowing PDS Biotech to maintain focus on their core immuno-oncology programs, including the VERSATILE-003 Phase 3 trial for HPV-positive head and neck cancer.

#PDSB PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

www.stocktitan.net/news/PDSB/pds-biotech-an...

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its Q1 2025 financial results conference call and webcast for May 14, 2025, at 8:00 AM ET. The company will present its financial performance for the quarter ending March 31, 2025, along with updates on its clinical programs. Investors can join via phone (1-877-704-4453 domestic, 1-201-389-0920 international) or through the webcast. The presentation will be archived on PDS Biotech's website for six months following the live event.

#PDSB PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

www.stocktitan.net/news/PDSB/pds-biotech-an...

On May 8th, Karl Subban will be speaking to parents & caregivers at Glenhaven Sr. P. S. Hope you can join! #pdsb

Hope to see you all on May 21 at the Black author’s book fair. See flyer for details! #pdsb

Groundbreaking Cancer Immunotherapy Data: NCI Reveals PDS01ADC Clinical Results NCI researchers unveil novel IL-12 immunotherapy data showing T-cell responses in advanced solid tumors. Key findings from PDS Biotech's PDS01ADC study inside.

#PDSB PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

www.stocktitan.net/news/PDSB/pds-biotech-an...

#aboutlastweek last week Friday we had decade day for spirit week. Can you guess the decade? #pdsb